Eloïse Laouenan Presents the Results of HEMOTHEPP-CHU Brest-GETBO Prospective Study
Eloïse Laouenan, PhD student in Life and Health Sciences, INSERM, shared on LinkedIn:
”Thanks to the CNGOF and the Pari(s) Santé Femmes congress for this opportunity to present the results of the epidemiology of VTE in the HEMOTHEPP/CHU Brest/GETBO prospective multicenter cohort study (20,238 unselected pregnant women included at delivery, followed 3 months).
Upcoming publication…
– High incidence of postpartum VTE
– Under-prescription of thromboprophylaxis
– Half of VTEs after 7 days postpartum
– High incidence in women at intermediate risk, with or without thromboprophylaxis
VTE risk assessment +++
Perspective: MUM-VTE CHU Brest/GETBO equals multicenter randomized controlled trial (F-CRIN INNOVTE) to evaluate the efficacy and safety of postpartum thromboprophylaxis in women at intermediate risk.
Thanks to all the patients and investigators.
Personal thanks to my team at Service de gynécologie obstétrique et médecine de la reproduction – CHU Brest !!!
Thanks for the photo and support!”
Stay updated with Hemostasis Today.
-
Dec 7, 2025, 17:01Abdul Mannan: How Do You Manage a Major Surgery When Blood Transfusion is Impossible?
-
Dec 7, 2025, 16:51Ahmed Bahi on Lina Merghani’s Critique of Early Withdrawal of Aspirin after PCI
-
Dec 7, 2025, 16:21Jonathan Douxfils: Can We Estimate the VTE Risk of a Pill Before a Million Women Use It?
-
Dec 7, 2025, 16:06Pablo Corral on Why Early LDL-C Reduction Saves Lives
-
Dec 7, 2025, 15:53Paul Batty Congratulates Giulia Simini on Taking The Joint BSH-ASH Abstract Award
-
Dec 7, 2025, 15:35Federica Fogacci Presents The New ILEP Consensus Paper
-
Dec 7, 2025, 15:20Deep Molecular Modeling for Type 2A VWD from Omid Seidizadeh
-
Dec 6, 2025, 18:02ASH25 Day 1: Don’t Miss The Highlights
-
Dec 6, 2025, 15:44Atul Gupta on Where The Healthcare Innovation is Headed